INTRODUCTION: We sought to determine the impact of salvage radio-therapy (SRT) on oncological and functional outcomes of patients with prostate cancer after biochemical recurrence (BCR) following robot-assisted radical prostatectomy (RARP). METHODS: Data of 70 patients with prostate cancer treated with SRT after developing BCR were retrospectively analyzed from a prospectively collected RARP database of 740 men. Oncological (prostate-specific antigen [PSA]) and functional (pads/day, International Prostate Symptom Score [IPSS], and Sexual Health Inventory for Men [SHIM]) outcomes were reported at six, 12, and 24 months after RT and adjusted for pre-SRT status. RESULTS: Men who underwent SRT had a mean age, PSA, and time from radical prostatectomy (RP) to RT of 61.8 years (60.1-63.6), 0.5 ng/ml (0.2-0.8), and 458 days (307-747), respectively. Freedom from biochemical failure (FFBF) post-SRT, defined as a PSA nadir <0.2 ng/mL, was observed in 89%, 93%, and 81%, at six, 12, and 24 months, respectively. Undetectable PSA was observed in 14%, 35%, and 40% at the same time points, respectively. There was no significant difference in urinary continence post-SRT (p=0.56). Rate of strict continence (0 pads/day) was 71% at 24 months compared to 78% pre-SRT. Mean IPSS at six, 12, and 24 months was 3.4, 3.6, and 3.6, respectively compared to pre-RT score of 3.3 (p=0.61). The mean SHIM score pre-SRT was comparable at all time points following treatment (p=0.86). CONCLUSIONS: In this unique Canadian experience, it appears that early SRT is highly effective for the treatment of BCR following RARP with little impact on urinary continence and potency outcomes.
INTRODUCTION: We sought to determine the impact of salvage radio-therapy (SRT) on oncological and functional outcomes of patients with prostate cancer after biochemical recurrence (BCR) following robot-assisted radical prostatectomy (RARP). METHODS: Data of 70 patients with prostate cancer treated with SRT after developing BCR were retrospectively analyzed from a prospectively collected RARP database of 740 men. Oncological (prostate-specific antigen [PSA]) and functional (pads/day, International Prostate Symptom Score [IPSS], and Sexual Health Inventory for Men [SHIM]) outcomes were reported at six, 12, and 24 months after RT and adjusted for pre-SRT status. RESULTS:Men who underwent SRT had a mean age, PSA, and time from radical prostatectomy (RP) to RT of 61.8 years (60.1-63.6), 0.5 ng/ml (0.2-0.8), and 458 days (307-747), respectively. Freedom from biochemical failure (FFBF) post-SRT, defined as a PSA nadir <0.2 ng/mL, was observed in 89%, 93%, and 81%, at six, 12, and 24 months, respectively. Undetectable PSA was observed in 14%, 35%, and 40% at the same time points, respectively. There was no significant difference in urinary continence post-SRT (p=0.56). Rate of strict continence (0 pads/day) was 71% at 24 months compared to 78% pre-SRT. Mean IPSS at six, 12, and 24 months was 3.4, 3.6, and 3.6, respectively compared to pre-RT score of 3.3 (p=0.61). The mean SHIM score pre-SRT was comparable at all time points following treatment (p=0.86). CONCLUSIONS: In this unique Canadian experience, it appears that early SRT is highly effective for the treatment of BCR following RARP with little impact on urinary continence and potency outcomes.
Authors: Alberto Briganti; Thomas Wiegel; Steven Joniau; Cesare Cozzarini; Marco Bianchi; Maxine Sun; Bertrand Tombal; Karin Haustermans; Tom Budiharto; Wolfgang Hinkelbein; Nadia Di Muzio; Pierre I Karakiewicz; Francesco Montorsi; Hein Van Poppel Journal: Eur Urol Date: 2012-05-16 Impact factor: 20.096
Authors: Ahmed Abugharib; William C Jackson; Vasu Tumati; Robert T Dess; Jae Y Lee; Shuang G Zhao; Moaaz Soliman; Zachary S Zumsteg; Rohit Mehra; Felix Y Feng; Todd M Morgan; Neil Desai; Daniel E Spratt Journal: J Urol Date: 2016-09-07 Impact factor: 7.450
Authors: Richard K Valicenti; Ian Thompson; Peter Albertsen; Brian J Davis; S Larry Goldenberg; J Stuart Wolf; Oliver Sartor; Eric Klein; Carol Hahn; Jeff Michalski; Mack Roach; Martha M Faraday Journal: Int J Radiat Oncol Biol Phys Date: 2013-08-01 Impact factor: 7.038
Authors: Henk G van der Poel; Corinne Tillier; Willem de Blok; Cenk Acar; Erik H A M van Muilekom Journal: Urology Date: 2013-08-22 Impact factor: 2.649
Authors: David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096